Stock Analysts’ upgrades for Thursday, September 7th:
Agenus (NASDAQ:AGEN) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.
Allete (NYSE:ALE) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Catalent (NASDAQ:CTLT) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
CytoDyn (NASDAQ:CYDY) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.
Dynavax Technologies Corporation (NASDAQ:DVAX) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.
El Paso Electric (NYSE:EE) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
EOG Resources (NYSE:EOG) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.
Harmony Gold Mining Company Limited (NYSE:HMY) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Hennes & Mauritz AB (OTCMKTS:HNNMY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.50 target price on the stock. According to Zacks, “H & M Hennes & Mauritz AB offers fashion products with a broad and varied selection for women, men, teens and children through retail outlets mainly in Europe. The Company also sells its products via catalogues and the Internet. The women’s collection includes basics to tailored classics, sportswear, maternity clothes, accessories and shoes. The men’s collections include tailored pieces, modern basics, leisurewear accessories, underwear and shoes. The jeans & denim includes traditional five-pocket jeans, trendy fashion jeans and denim models in organic cotton. H&M’s cosmetics department provides a wide range of makeup, skin care and body care products. H & M Hennes & Mauritz AB is a subsidiary of Ramsbury Invest AB and is headquartered in Stockholm, Sweden. “
Histogenics Corporation (NASDAQ:HSGX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $2.00 target price on the stock. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Orix Corp Ads (NYSE:IX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $89.00 target price on the stock. According to Zacks, “ORIX CORP-ADR is a diversified financial services institution with diverse operations in both corporate and retail finance, including: leasing, lending, rentals, life insurance, real estate financing and development, venture capital, investment and retail banking, commodities funds and securities brokerage. Their international operations include leasing, rentals, fixed income investment, aircraft and ship financing, commercial mortgage servicing and property development. “
Jabil Circuit (NYSE:JBL) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.
NewLink Genetics Corp (NASDAQ:NLNK) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.
National Bank of Canada (OTCMKTS:NTIOF) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.
PACCAR (NASDAQ:PCAR) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
PNM Resources, Inc. (Holding Co.) (NYSE:PNM) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Rockwell Automation (NYSE:ROK) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Schmitt Industries (NASDAQ:SMIT) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Titan Machinery (NASDAQ:TITN) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.
